Abstract：
Chronic myeloid leukaemia (CML) is caused by BCR::ABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.
摘要：
慢性髓性白血病（CML）由BCR::ABL1引起。酪氨酸激酶抑制剂(TKIs)是初始疗法。一些组织已经报告了评估对初始TKI治疗的反应的里程碑，并建议何时应考虑改变TKI。实现无治疗缓解（TFR）越来越被认为是最佳治疗目标。哪种TKI是最佳的初始疗法，以及实现TFR需要什么深度和持续时间的分子缓解是有争议的。在这篇综述中，我们讨论了这些问题，并提出了未来的研究方向。
